Evidence map›Paper›PMID 39472505›Full record

ArticleScientific reports2024

Time to consider ruling out inclusion bodies denaturing protocols for spontaneous solubilization of biologically active proteins.

Ricardo Baltà-Foix, Elena Garcia-Fruitós, Anna Arís

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Interferon Lambda: The Next Frontier in Antiviral Therapy?Pharmaceuticals (Basel, Switzerland) · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ricardo Baltà-FoixRuminant Production, IRTA, Torre Marimon, 08140, Caldes de Montbui, Catalonia, Spain.
Elena Garcia-Fruitós *Ruminant Production, IRTA, Torre Marimon, 08140, Caldes de Montbui, Catalonia, Spain. elena.garcia@irta.cat.
Anna Arís *Ruminant Production, IRTA, Torre Marimon, 08140, Caldes de Montbui, Catalonia, Spain. anna.aris@irta.cat.

Funding

AGAUR 2021 SGR 01552.Ministerio de Ciencia, Innovación y Universidades Grants PID2019-107298RB-C21/AEI/10.13039/ 501100011033
6 · The paper itself

Abstract

The formation of inclusion bodies (IBs) in microbial cell factories is a very common process occurring during recombinant protein production. Different protocols have been developed for the extraction of soluble proteins from IBs using several strategies, ranging from the use of harsh denaturing and high concentrations of chaotropic agents and reducing agents to the use of mild protocols based on the use of non-denaturing detergents. However, in recent years, the biological vision of IBs has changed and research studies have demonstrated that these protein aggregates contain biologically active and properly folded recombinant proteins. This drives us to redefine the methodologies currently used to obtain soluble protein using IB as a protein source. Hence, we propose the extraction of IB protein via the simple spontaneous solubilization of IB as a strategy broadly applicable to all kinds of recombinant proteins without the negative effects of detergents and chaotropic agents on final biological activity. We prove the wide applicability of spontaneous solubilization processes to different types of IBs and that protocols can be easily customized for each protein in terms of timing and incubation temperature by monitoring the protein activity of the solubilized fraction.

Indexed as

Inclusion BodiesRecombinant ProteinsSolubilityDetergentsEscherichia coliProtein DenaturationProtein FoldingDetergentsRecombinant ProteinsActivity assayInclusion bodiesRecombinant productionSolubilization

Identifiers

PMID39472505
PMCPMC11522400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.